Ionis Pharmaceuticals (IONS) Accumulated Expenses (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Accumulated Expenses of $115.8 million for Q2 2026, up 17.0% year-over-year from $99.0 million in Q2 2025, and down 8.51% quarter-over-quarter from $126.5 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Accumulated Expenses (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $115.8 million for Q2 2026.
- In Q2 2026, Accumulated Expenses rose 17.0% year-over-year to $115.8 million; the TTM figure through Jun 2026 stood at $115.8 million (up 17.0% YoY), while the FY2025 annual figure was $116.2 million, up 7.19% from the prior year.
- Accumulated Expenses for Q2 2026 stood at $115.8 million, down from $126.5 million in the prior quarter.
- The five-year high for Accumulated Expenses was $147.9 million in Q4 2023, with the low at $99.0 million in Q2 2025.
- The 5-year median for Accumulated Expenses is $115.1 million (2024), against an average of $116.6 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 78.76% in 2022, then declined 26.68% in 2024.
- Ionis Pharmaceuticals' Accumulated Expenses stood at $140.1 million in 2022, then rose by 5.56% to $147.9 million in 2023, then dropped by 26.68% to $108.4 million in 2024, then climbed by 7.19% to $116.2 million in 2025, then declined by 0.39% to $115.8 million in 2026.
- Business Quant data shows IONS's Accumulated Expenses at $115.8 million in Q2 2026, $126.5 million in Q1 2026, and $116.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.78 Mn |
| Mar 31, 2026 | 126.55 Mn |
| Dec 31, 2025 | 116.24 Mn |
| Sep 30, 2025 | 99.31 Mn |
| Jun 30, 2025 | 98.96 Mn |
| Mar 31, 2025 | 102.74 Mn |
| Dec 31, 2024 | 108.44 Mn |
| Sep 30, 2024 | 124.40 Mn |
| Jun 30, 2024 | 114.33 Mn |
| Mar 31, 2024 | 106.05 Mn |
| Dec 31, 2023 | 147.89 Mn |
| Sep 30, 2023 | 118.97 Mn |
| Jun 30, 2023 | 104.75 Mn |
| Mar 31, 2023 | 112.70 Mn |
| Dec 31, 2022 | 140.10 Mn |
| Sep 30, 2022 | 128.00 Mn |
| Jun 30, 2022 | 134.34 Mn |
| Mar 31, 2022 | 99.26 Mn |
| Dec 31, 2021 | 88.56 Mn |
| Sep 30, 2021 | 75.68 Mn |